Morrisville clinical-stage biotech engineering bacteriophage therapeutics with CRISPR-Cas3 payloads for antimicrobial-resistant bacterial infections and microbiome / inflammatory diseases.
At a glance
- HQ: Morrisville
- Sector: Biotech
- Stage: Series B
- Total raised: $35M
- Affiliation: NC State
Where the team studied
Filter the directory by schoolDuke University
- Dave OusteroutAlumPh.D., Biomedical Engineering
North Carolina State University
- Chase BeiselFacultyAssistant Professor (later Associate Professor with tenure), Department of Chemical and Biomolecular EngineeringSource
- Paul GarofoloFacultyVisiting Professor, Poole College of ManagementSource
- Rodolphe BarrangouFacultyProfessor of Food ScienceSource
Each line was checked against a primary source. Founder education is recorded for part of the directory, so a name missing here is a gap in what has been checked, not a statement that they studied somewhere else. Tell me what is missing.
Open roles
All open Triangle rolesThe rest of this record is behind a free account.
Founders, funding history, investor connections, and recent signals load on this page as soon as you sign in. Accounts open immediately, and I read every signup.